The grades of seven Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Flamel Technologies (NASDAQ:FLML) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Flamel Technologies develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. For more information, get Portfolio Grader’s complete analysis of FLML stock.
Questcor Pharmaceuticals (NASDAQ:QCOR) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Questcor Pharmaceuticals develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The stock price has risen 30% over the past month, better than the 4.4% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of QCOR stock.
Eli Lilly (NYSE:LLY) boosts its rating from a B to an A this week. Eli Lilly discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. Wall Street has pushed the stock higher by 10.1% over the past month. For more information, get Portfolio Grader’s complete analysis of LLY stock.
XenoPort (NASDAQ:XNPT) shows solid improvement this week. The company’s rating rises from a C to a B. XenoPort is a biopharmaceutical company that focuses on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 15.1% over the past month. For more information, get Portfolio Grader’s complete analysis of XNPT stock.
This week, Valeant Pharmaceuticals (NYSE:VRX) pushes up from a C to a B rating. Biovail Corporation International develops and distributes drugs. Wall Street seems to agree with the upgrade and has propelled the stock up 17.4% over the past month. For more information, get Portfolio Grader’s complete analysis of VRX stock.
Acura Pharmaceuticals (NASDAQ:ACUR) earns a B this week, jumping up from last week’s grade of C. Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. Investors have pushed the stock price up 31.5% over the past month. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
Sanofi (NYSE:SNY) gets a higher grade this week, advancing from a C last week to a B. Sanofi-Aventis researches, develops, manufactures and markets healthcare products, particularly pharmaceuticals and human vaccines. Over the last month, the price of SNY has increased 5.4%. For more information, get Portfolio Grader’s complete analysis of SNY stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
